• Publications
  • Influence
Combination checkpoint immunotherapy and cytotoxic chemotherapy: Pembrolizumab (Pembro) plus either docetaxel or gemcitabine in patients with advanced or metastatic urothelial cancer.
Results from the initial cohort of an investigator-initiated trial of Pembro plus either docetaxel or gemcitabine in platinum-treated mUC patients are reported, with primary endpoint was safety and secondary endpoints were overall RR and progression-free survival (PFS). Expand
A potent, nonpeptidyl 1H-quinolone antagonist for the gonadotropin-releasing hormone receptor.
Quinolone 1 is a potent nonpeptidyl antagonist for the human GnRH receptor that is efficacious for the suppression of luteinizing hormone and testosterone in primates. Expand
Inverse electron demand diels-alder reactions of indole IV. A new route to β-carbolines
Abstract β-Carbolines have been prepared by the intramolecular cycloaddition of indole with 1,2,4-triazines tethered from C3 with the indolyl nitrogen using a thiourea linkage. Subsequent to theExpand
Heterocyclic derivatives of 2-(3,5-dimethylphenyl)tryptamine as GnRH receptor antagonists.
A series of heterocyclic 2-(3,5-dimethylphenyl)tryptamine derivatives was prepared and evaluated on a rat gonadotropin releasing hormone receptor assay, with the most potent compound having an IC50 of 16 nM. Expand
New and emerging developments in extensive-stage small cell lung cancer therapeutics
Extensive-stage small cell lung cancer (ES-SCLC) remains a disease with a dismal prognosis, with median survival of approximately 8–10 months, but there have been recent advances in the use of radiation therapy, as well as new insights into the biology of SCLC. Expand
Enzalutamide and metformin combination therapy to overcome autophagy resistance in castration resistant prostate cancer (CRPC): Current results from a phase I study.
A Phase I clinical trial evaluating the combination of metformin and enza to establish the maximum tolerated dose (MTD), with secondary objectives of evaluating PSA response o... Expand
Identification of neutral 4-O-alkyl quinolone nonpeptide GnRH receptor antagonists.
Potent neutral GnRH antagonists were identified, including ether and lactam derivatives, that show similar in vitro binding affinity and functional activity as compared to the earlier basic 4-aminoalkyl quinolone series of nonpeptide Gn RH antagonists. Expand
Evaluation of clinical pharmacy services within the primary care–mental health integration model at the Tuscaloosa Veterans Affairs Medical Center
The results support the significance of CPS in the PCMHI in providing pharmacotherapy, patient education, and medication monitoring for managing psychiatric conditions, such as depression, anxiety, and insomnia. Expand
Niclosamide in combination with abiraterone and prednisone in men with castration-resistant prostate cancer (CRPC): initial results from a phase Ib/II trial.
It is hypothesize that niclosamide/PDMX1001 potentiates the efficacy of Abi against CRPC and will enroll 27 patients with detectable AR-V7 in the peripheral blood in the Phase II trial. Expand